120747-84-4

Usage

Chemical Properties

Light brown solid

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 28, p. 1281, 1991 DOI: 10.1002/jhet.5570280520

InChI:InChI=1/C5H5N3O/c6-5-7-1-4(3-9)2-8-5/h1-3H,(H2,6,7,8)

Upstream product

• 18655-47-5 triformylmethane 
• 50-01-1 guanidine hydrochloride 
• 124-46-9 guanidine hydrogen carbonate 
• 2009-81-6 2-dimethylaminomethylene-1,3-bis(dimethylimonio)propane diperchlorate 
• 73312-68-2 1-(dimethylamino)ethylene-2,2-dicarboxaldehyde 
• 933702-55-7 2‐chloropyrimidine-5-carbaldehyde 
• 308348-93-8 2-amino-pyrimidine-5-carboxylic acid methyl ester 

Downstream Products

• 257290-68-9 N-[5-(5,5-dimethyl-[1,3]dioxan-2-yl)-pyrimidin-2-yl]-4-methyl-benzenesulfonamide 
• 257290-80-5 2-[5-(5,5-dimethyl-[1,3]dioxan-2-yl)-2-(toluene-4-sulfonylimino)-2H-pyrimidin-1-yl]-acetamide 
• 258276-64-1 HIP-2 
• 258276-66-3 HIP-3 
• 862096-02-4 C₅H₆N₄O 

Relevant academic research and scientific papers

Benzimidazole derivatives, preparation methods and uses theirof

The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.

NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME

Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Compounds and methods for kinase modulation, and indications therefor

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereo

AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

This invention relates to novel 2,3-dihydroimidazo[1,2 -c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/ or angiogenesis disorders, as a sole agent or in combination with other active ingredients

PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

INDOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS

Disclosed are novel compounds of the formula I wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a H1 receptor antagonist.

Formation of Pyrimidine-5-carboxaldehydes, 1-Aminoethylene-2,2-dicarboxaldehyde and 2-Amino-4-anilino-1,3,5-triazine from Triformylmethane and Amidines

Triformylmethane (1) reacted with benzamidine, guanidine and S-methylisothiourea to give the corresponding 2-substituted pyrimidines-5-carboxaldehydes.However reactions of 1 with acetamidine (or formamidine) and phenylbiguanide gave the unexpected 1-aminoethylene-2,2-dicarboxaldehyde (5) and 2-amino-4-anilino-1,3,5-triazine (9), respectively.

An Alternative Preparation of the 2-Dimethylaminomethylene-1,3-bis(dimethylimminio)propane Salt from Phosphonoacetic Acids and Some Applications in Heterocyclic Synthesis

An alternative preparation of a 2-iminovinamidinium salt from phosphonoacetic acids is described along with its application to the synthesis of 5-formylpyrimidines and masked 4-formylpyrazoles.

DIRECT SYNTHESIS OF 2-SUBSTITUTED 5-FORMYLPYRIMIDINES AND RING TRANSFORMATION OF THEIR PHENYLHYDRAZONES INTO 4-FORMYL-1-PHENYLPYRAZOLE

Triformylmethane (1) reacted with benzamidine, guanidine and S-methylisothiourea to give 2-substituted 5-formylpyrimidines (2a-c), whose phenylhydrazones (3a-c) readily underwent ring transformation into 4-formyl-1-phenylpyrazole (4) on heating in acidic methanol.